Covid-19 vaccine: Panel of experts recommends emergency approval for Russia’s Sputnik V.


(Image source: Reuters)

In a key development, a panel of experts has recommended the use of Sputnik V – a COVID-19 vaccine developed by Russia – in India under certain emergency conditions. The final decision will be made by the Drugs Controller General of India (DCGI). Once approved, it will be used in India by Dr. Reddy’s Laboratories, a major pharmaceutical company, was introduced. Once that is done, it will be the third COVID-19 vaccine available in India.

“The Technical Expert Committee approves Dr. Reddy’s application for emergency approval at Sputnik V,” ANI sources quoted as saying.

Like other vaccines used in India, Sputnik V is a two-dose vaccine. The second nap of the vaccine will be given 21 days after receiving the first dose. According to Deepak Sapra, CEO, APIs and Services at Dr. Reddy, maximum immunity is developed between the 28th and 42nd day.

The Committee of Experts approves Dr. Reddy for approval for an emergency at Sputnik V: Sources # COVID19

– ANI (@ANI) April 12, 2021

Dr. Reddys has partnered with the Russia Direct Investment Fund (RDIF) to bring the vaccine to India. The partnership was signed last September.

Oxford-AstraZeneca’s Covishield and Covaxin, which are being developed by Bharat Biotech, have already received emergency clearance from the Drugs Controller General of India. Covishield is made by the Serum Institute of India in Pune.

Sputnik V from Russia has demonstrated an effectiveness rate of 91.6 percent in the interim analysis of the clinical phase 3 study.

Get live stock quotes from BSE, NSE, the US market and the latest net asset value, mutual fund portfolio, read the latest IPO news, best performing IPOs, calculate your taxes with the Income Tax Calculator, you know them Top gainers, top losers and best equity funds in the market. Like us on Facebook and follow us on Twitter.

Financial Express is now in the telegram. Click here to join our channel and stay up to date with the latest news and updates from Biz.


Steven Gregory